The Joint Annual Scientific Meetings of the Endocrine Society of Australia and the Society for Reproductive Biology 2018

Maternal metyrapone use during breastfeeding: safe for the breastfed infant (#213)

Madeline Duke 1 2 , Helen Barrett 2 , Carel Pretorius 3 , Fiona Britten 4 , Peter Donovan 1 5
  1. Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
  2. Obstetric Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
  3. Chemical Pathology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
  4. Obstetric Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
  5. Clinical Pharmacology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia

Abstract:

Context: Metyrapone is an inhibitor of endogenous adrenal corticosteroid synthesis which has been proven to be a viable and safe option in controlling maternal serum cortisol concentrations during pregnancy. The infant exposure to maternally ingested metyrapone through breast milk is, however, largely unknown.

Case Description: We report the excretion of metyrapone into breast milk and subsequent infant exposure from a lactating woman on 250mg of metyrapone three times daily. At steady state, the average concentrations in milk and absolute and relative infant doses (AID and RID) were 176 ug/L, 26.45 ug/kg/d, and 0.7% respectively for metyrapone, and 310 ug/L, 46.52 ug/kg/d, and 1.21% for its active metabolite rac-metyrapol. The breastfed infant was found to have a plasma metyrapone concentration of 0.05 ug/L, with no evidence of disruption to his adrenocortical axis biochemically.

Conclusion: These findings indicate that maternal metyrapone use during breastfeeding did not pose a significant risk to the breastfed infant.

  1. 1. Novartis Pharmaceuticals Corporation, Metyripone Drug information Sheet Reference ID: 2859992
  2. 2. Hotham N, Ilett K, Hackett L, Morton M, Muller P, Hague W. Transfer of Metyrapone and Its Metabolite, rac-Metyrapol, Into Breast Milk. Journal of Human Lactation. 2009;25(4):451-454.
  3. 3. McWhinney BC, Briscoe SE, Ungerer JPJ, Pretorius CJ. Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11-deoxycortisol with ultra high performance liquid chromatography–tandem mass spectrometry: application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory. Journal of Chromatography B 2010;878:2863-2869.
  4. 4. Begg E, Duffull S, Hackett L, Ilett K. Studying Drugs in Human Milk: Time to Unify the Approach. Journal of Human Lactation. 2002;18(4):323-332.
  5. 5. BNF for children 2011-2012. London: BMJ Group; 2011.
  6. 6. Neville M, Walsh C. Effects of drugs on milk secretion and composition. In:Bennett PN, ed. Drugs and Human Lactation. Amsterdam:Elsevier; 1996:15-46.